At the studys conclusion, researchers found that in all dosages, participants taking elecoglipron experienced a decrease in their glucose levels significantly more than those taking the placebo after 26 weeks
no insurance required Key exclusions / pregnancy, breastfeeding, personal or family history of medullary thyroid carcinoma or MEN2 Expected weight loss (GLP-1 class) / 10-22% body weight over 68-72 weeks per published RCT data Visit format / asynchronous messaging plus scheduled video consults depending on plan tier Compounded vs
The FDA has posted a notice about the recall of continuous glucose monitors from Abbott
Report mood changes to your PlexusDx provider immediately, including depressive symptoms, emotional numbness, or loss of motivation lasting more than two weeks
Second, the employer-facing expansion of Cost Plus, particularly through the CenterWell/Humana partnership announced in April 2026, is changing plan sponsor expectations about drug pricing in ways that affect formulary negotiations for in-patent drugs today
The company is leveraging its diagnostics and digital health expertise to create integrated metabolic disease management solutions around GLP-1 therapies
